Zobrazeno 1 - 10 of 81 pro vyhledávání: '"Cody, Peer"'
1
Akademický článek
Pharmacokinetics and pharmacogenomics of ribociclib in black patients with metastatic breast cancer the LEANORA study
Autor: Ilana Schlam, D. Max Smith, Cody Peer, Tristan Sissung, Keith T. Schmidt, Ming Tan, Ami Chitalia, Nanette H. Bishopric, Seth Steinberg, Hyoyoung Choo-Wosoba, Giulia Napoli, Christopher Gallagher, Nadia Ashai, Kristen Whitaker, Candace Mainor, Shruti Tiwari, Nicole Swanson, Stacy Malloy, Claudine Isaacs, William Douglas Figg, Sandra M. Swain
Publikováno v: npj Breast Cancer, Vol 10, Iss 1, Pp 1-9 (2024)
Abstract Underrepresented populations’ participation in clinical trials remains limited, and the potential impact of genomic variants on drug metabolism remains elusive. This study aimed to assess the pharmacokinetics (PK) and pharmacogenomics (PGx
Externí odkaz: https://doaj.org/article/ad6ed8bebf71498f80dbc2876ee15de4
Zobrazit plný text záznamu
2
Akademický článek
Systemic Treatment with the Janus Kinase Inhibitor Baricitinib in Ocular Chronic Graft-versus-Host Disease
Autor: Taylor McManus, BS, MS, Noa G. Holtzman, MD, Aaron Zhao, BS, Chantal Cousineau-Krieger, MD, Susan Vitale, PhD, MHS, Edmond J. FitzGibbon, MD, Debbie Payne, BS, MBA, Janine Newgen, COT, Celestina Igbinosun, BSN, RN, Annie P. Im, MD, Cody Peer, MS, PhD, William Douglas Figg, Sr., Pharm D, Edward W. Cowen, MD, Jacqueline W. Mays, DDS, PhD, Steven Pavletic, MD, PhD, M.Teresa Magone, MD
Publikováno v: Ophthalmology Science, Vol 5, Iss 1, Pp 100627- (2025)
Objective: To investigate the effects of oral baricitinib on ocular surface disease (OSD) in patients with chronic graft-versus-host disease (cGVHD). Design: Prospective phase 1 to 2 single institution trial. Subjects: Eighteen patients with ocular g
Externí odkaz: https://doaj.org/article/877ccca9a34547dd8a20cab8fdca5d2a
Zobrazit plný text záznamu
3
Akademický článek
First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors
Autor: Christopher B. Cole, Maria Pia Morelli, Massimo Fantini, Markku Miettinen, Patricia Fetsch, Cody Peer, William D. Figg, Tyler Yin, Nicole Houston, Ann McCoy, Stanley Lipkowitz, Alexandra Zimmer, Jung-min Lee, Miroslava Pavelova, Erin N. Villanueva, Kathryn Trewhitt, B. Brooke Solarz, Maria Fergusson, Sharon A. Mavroukakis, Anjum Zaki, Kwong Y. Tsang, Philip M. Arlen, Christina M. Annunziata
Publikováno v: Journal of Experimental & Clinical Cancer Research, Vol 42, Iss 1, Pp 1-17 (2023)
Abstract Background NEO201 is a humanized IgG1 monoclonal antibody (mAb) generated against tumor-associated antigens from patients with colorectal cancer. NEO-201 binds to core 1 or extended core 1 O-glycans expressed by its target cells. Here, we pr
Externí odkaz: https://doaj.org/article/156401e08d7b44f9b984a38a26842574
Zobrazit plný text záznamu
4
Akademický článek
Clinical protocol: Feasibility of evaluating abemaciclib neuropharmacokinetics of diffuse midline glioma using intratumoral microdialysis.
Autor: Edjah K Nduom, John Glod, Desmond A Brown, Margaret Fagan, Mahalia Dalmage, John Heiss, Seth M Steinberg, Cody Peer, William D Figg, Sadhana Jackson
Publikováno v: PLoS ONE, Vol 18, Iss 9, p e0291068 (2023)
Diffuse midline gliomas (DMG) are the most aggressive brain tumors of childhood and young adults, with documented 2-year survival rates 10nmol/L, or tumor tissue studies demonstrate CDK inhibition, then restart of abemaciclib therapy along with temoz
Externí odkaz: https://doaj.org/article/9f638dbd977f45b4ae901004683c5452
Zobrazit plný text záznamu
6
Akademický článek
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses
Autor: Alexandra S. Zimmer, Erin Nichols, Ashley Cimino-Mathews, Cody Peer, Liang Cao, Min-Jung Lee, Elise C. Kohn, Christina M. Annunziata, Stanley Lipkowitz, Jane B. Trepel, Rajni Sharma, Lekha Mikkilineni, Margaret Gatti-Mays, William D. Figg, Nicole D. Houston, Jung-Min Lee
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-8 (2019)
Abstract Background Strategies to improve activity of immune checkpoint inhibitors are needed. We hypothesized enhanced DNA damage by olaparib, a PARP inhibitor, and reduced VEGF signaling by cediranib, a VEGFR1–3 inhibitor, would complement anti-t
Externí odkaz: https://doaj.org/article/eb461ecb544343d883020500c12dca8f
Zobrazit plný text záznamu
8
Akademický článek
The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma
Autor: Sadhana Jackson, Jon Weingart, Edjah K. Nduom, Thura T. Harfi, Richard T. George, Dorothea McAreavey, Xiaobu Ye, Nicole M. Anders, Cody Peer, William D. Figg, Mark Gilbert, Michelle A. Rudek, Stuart A. Grossman
Publikováno v: Fluids and Barriers of the CNS, Vol 15, Iss 1, Pp 1-9 (2018)
Abstract Background The blood–brain barrier (BBB) severely limits the entry of systemically administered drugs including chemotherapy to the brain. In rodents, regadenoson activation of adenosine A2A receptors causes transient BBB disruption and in
Externí odkaz: https://doaj.org/article/38bb304a8ef54edb86d7eee7cfa253e3
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje